DelveInsight Blog

Pharma M&A Rebound May Take a While i...
Dec 22, 2016
The only word that described 2016’s pharma M&A market was “slow.” Some do predict that new year—and administratio...

Assessing the Growing Role & the Dema...
May 11, 2022
Over the past few years, the prevalence of the chronic disease has grown significantly. The rising prevalence is lead...

AstraZeneca’s Farxiga; Incyte’s Jakavi; FD...
May 10, 2022
AstraZeneca’s Farxiga Meets Primary Endpoints in Phase 3 Heart Failure Trial Farxiga, an SGLT2 inhibitor from AstraZe...
Sign Up and Stay Informed
Penetrative insights and rich analysis of Pharma, Biotech and MedTech space.
Editor's Pick
Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU ...
Patent protection and expiration is one of the hot topics in the healthcare industry. P...
What are the Top 9 Most Common Food Allergies and How Pharma Companies are Ta...
Food Allergies is a major concern for a wide spectrum of populations globally. Accordin...
Evaluating the Top Players in the Global Bone Densitometers Market
Bone densitometers are the diagnostic systems with an enhanced X-ray technology known a...
Mapping the Biggest Pharmaceutical Companies by Continents
Today, the most important factor affecting the world’s economy is the Global Pharmaceut...
Robotic Surgery: Navigating the Growing Demand, Ongoing Trends & Develop...
It's no longer startling to learn that the best-performing surgeon at a hospital isn't ...
RECENT ARTICLES